Caceres V M, Stange K C, Kikano G E, Zyzanski S J
Family Practice Residency Program, University Hospitals of Cleveland, OH 44106.
J Fam Pract. 1994 Oct;39(4):337-9.
This study was undertaken to investigate the clinical utility of a widespread practice: the 24-hour in-hospital observation period that commonly follows when the treatment of patients hospitalized with acute pyelonephritis is switched from intravenous to oral antibiotics. A preliminary survey of infectious disease specialists confirmed the pervasiveness of this practice and the lack of scientific evidence to support it.
The clinical utility of in-hospital observation was examined by means of a retrospective chart review of 138 consecutive nonpregnant adult patients who were between the ages of 17 and 65 and had been admitted to a university hospital with a diagnosis of acute pyelonephritis. The progress notes, temperature charts, and laboratory test results were reviewed for any evidence of clinical relapse or adverse reaction to the antibiotic that occurred in the 24-hour period after the switch from intravenous to oral antibiotic therapy.
Only two (1%) patients had evidence of clinical relapse within the study period. Five (4%) patients had adverse reactions to their oral antibiotic, none of which were serious. The 95% confidence interval for the percentage of patients who might experience a clinical relapse was from 1% to 5%; for adverse antibiotic reaction, 1% to 8%.
This study shows the limited usefulness of an in-hospital observation period. Savings resulting from avoiding an extra day of hospitalization could amount to millions of dollars annually in the United States.
本研究旨在调查一种普遍做法的临床实用性:急性肾盂肾炎住院患者的治疗从静脉注射抗生素改为口服抗生素后,通常进行的24小时住院观察期。对传染病专家的初步调查证实了这种做法的普遍性以及缺乏支持它的科学证据。
通过对138例连续的非妊娠成年患者进行回顾性病历审查,研究住院观察的临床实用性。这些患者年龄在17至65岁之间,因诊断为急性肾盂肾炎而入住大学医院。审查病程记录、体温图表和实验室检查结果,以寻找从静脉注射抗生素改为口服抗生素治疗后24小时内出现临床复发或抗生素不良反应的任何证据。
在研究期间,只有两名(1%)患者有临床复发的证据。五名(4%)患者对口服抗生素有不良反应,但均不严重。可能发生临床复发的患者百分比的95%置信区间为1%至5%;抗生素不良反应的置信区间为1%至8%。
本研究表明住院观察期的作用有限。在美国,避免额外一天住院所节省的费用每年可达数百万美元。